Floatz logo

Pentoxifylline

Doxorubicin

Mansoura UniversitySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Doxorubicin cohort.

Asset / SponsorPhaseRating
Inno-206
Tanta University
Phase 3BB
Cyclophosphamide
Mansoura University
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3B
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3B
Ciprofloxacin
National Cancer Institute (NCI)
Phase 3B

View all 12 →

Same molecule, other indications

Pentoxifylline is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative ·
76 / 100
View asset →
Neuralgia PeripheralDormant
BB
Indicative ·
69 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →